Association of Early Favipiravir Use with Reduced COVID-19 Fatality among Hospitalized Patients
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The antiviral agent favipiravir is an RNA-dependent RNA polymerase (RdRp) inhibitor. Materials and Methods: We examined patients with a clinical, laboratory, and radiological diagnosis of severe coronavirus disease 2019 (COVID-19) pneumonia. We investigated the effect of administering enteral favipiravir at a 2 × 1,600 mg loading dose and 2 × 600 mg maintenance dose for 5 days in addition to the standard COVID-19 treatment. Results: In total, 180 patients, who were hospitalized at the Istanbul Tuzla State Hospital and received favipiravir treatment between March 20, 2020 and May 30, 2020, were examined. Of these, 47 patients died. Thirty-three of the patients who died were aged over 65 years (70%), indicating that fatality was higher in elderly patients. Most of those who died had at least one comorbidity. Of the 101 patients who initiated favipiravir within ≤3 days of hospitalization, 17 died (17%). Of the 79 patients who initiated favipiravir after >3 days of hospitalization, 30 died (38%) (P = 0.002). Conclusion: We found that initiation of favipiravir within the first 72 h after the onset of disease symptoms reduced fatality in patients with COVID-19.
Abstract
Background: The antiviral agent favipiravir is an RNA-dependent RNA polymerase (RdRp) inhibitor. Materials and Methods: We examined patients with a clinical, laboratory, and radiological diagnosis of severe coronavirus disease 2019 (COVID-19) pneumonia. We investigated the effect of administering enteral favipiravir at a 2 × 1,600 mg loading dose and 2 × 600 mg maintenance dose for 5 days in addition to the standard COVID-19 treatment. Results: In total, 180 patients, who were hospitalized at the Istanbul Tuzla State Hospital and received favipiravir treatment between March 20, 2020 and May 30, 2020, were examined. Of these, 47 patients died. Thirty-three of the patients who died were aged over 65 years (70%), indicating that fatality was higher in elderly patients. Most of those who died had at least one comorbidity. Of the 101 patients who initiated favipiravir within ≤3 days of hospitalization, 17 died (17%). Of the 79 patients who initiated favipiravir after >3 days of hospitalization, 30 died (38%) (P = 0.002). Conclusion: We found that initiation of favipiravir within the first 72 h after the onset of disease symptoms reduced fatality in patients with COVID-19.
참고문헌 (27)
- Sallenave JM, "Innate immune signaling and proteolytic pathways in the resolution or exacerbation of SARS-CoV-2 in Covid-19: key therapeutic Targets?", Front Immunol, 11, pp.1229~ (2020)
- Helmy YA, "The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control", J Clin Med, 9, pp.1225~ (2020)
- Han W, "The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019", J Med Virol, 2, pp.61~63 (2020)
- Furuta Y, "Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase", Proc Jpn Acad Ser B Phys Biol Sci, 93, pp.449~463 (2017)
- Joshi S, "Role of favipiravir in the treatment of COVID-19", Int J Infect Dis, 102, pp.501~508 (2021)
- Du YX, "Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection", Clin Pharmacol Ther, 108, pp.242~247 (2020)
- Cai Q, "Experimental treatment with favipiravir for COVID-19: an open-label control study", Engineering (Beijing), 6, pp.1192~1198 (2020)
- Yang L, "COVID-19: immunopathogenesis and Immunotherapeutics", Signal Transduct Target Ther, 5, pp.128~ (2020)
- Vijayvargiya P, "Treatment considerations for COVID-19: a critical review of the evidence (or lack thereof )", Mayo Clin Proc, 95, pp.1454~1466 (2020)
- Xu X, "Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines", Mil Med Res, 7, pp.22~ (2020)
- Shakoory B, "Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase iII trial", Crit Care Med, 44, pp.275~281 (2016)
- Wang Y, "Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures", J Med Virol, 92, pp.568~576 (2020)
- Hsu J, "Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies", Ann Intern Med, 156, pp.512~524 (2012)
- Uyeki TM, "Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa", Clin Infect Dis, 68, pp.e1~e47 (2019)
- Chan KS, "Treatment of severe acute respiratory syndrome with lopinavir", ritonavir: a multicentre retrospective matched cohort study, 2003, pp.9, 399~406
- Magleby R, "Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019", Clin Infect Dis (2020)
- Weiss A, "Spatial and temporal dynamics of SARS-CoV-2 in COVID-19patients: a systematic review and meta-analysis", EBioMedicine, 58, pp.102916~ (2020)
- Goyal A, "Modeling HCV cure after an ultra-short duration of therapy with direct acting agents", Antiviral Res, 144, pp.281~285 (2017)
- McCullough PA, "Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection", Am J Med, 134, pp.16~22 (2021)
- Saber-Ayad M, "The Rationale for Potential Pharmacotherapy of COVID-19", Pharmaceuticals (Basel), 13, pp.96~ (2020)
- Yu T, "COVID-19 patients benefit from early antiviral treatment: A comparative, retrospective study", J Med Virol, 92, pp.2675~2683 (2020)
- Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA, 323, pp.1239~1242 (2020)
- Kim JS, "Immunopathogenesis and treatment of cytokine storm in COVID-19", Theranostics, 11, pp.316~329 (2021)
- Wu J, "Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)", J Intern Med, 288, pp.128~138 (2020)
- Kalil AC, "Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics", JAMA, 323, pp.1897~1898 (2020)
- Murohashi K, "Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: a report of 11 cases", Respir Investig, 58, pp.430~434 (2020)
- Doi Y, "A Prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19", Antimicrob Agents Chemother, 64, pp.e01897~e01820 (2020)